医脉通（02192）今日盘中表现亮眼，股价大涨7.99%，引发市场广泛关注。
消息面上，医脉通公布了2024年度业绩报告，显示公司各项财务指标均实现显著增长。据悉，公司全年收益约5.58亿元，同比增长35.5%；毛利约3.27亿元，同比增长30.2%；母公司拥有人应占溢利约3.15亿元，同比增长30.1%。基本每股盈利达43.23分，公司拟派末期股息每股0.1366元，较上年同期的0.1248元有所提升。值得注意的是，公司的精准营销及企业解决方案业务表现尤为出色，收入从2023年的3.727亿元大幅增长37.5%至5.125亿元。
分析人士指出，医脉通正在实施横向拓展和纵向深化的战略布局，不断延伸其价值链。公司围绕临床专科进行专科化建设与运营，扩大覆盖的科室、病种和产品营销范围。同时，公司也在药品临床研究、数字营销和患者管理等方面加强能力建设，通过投资并购实现对药企客户需求的全面覆盖。此外，公司正基于现有海量数据开发垂直大模型，进一步构建自身的竞争壁垒，这些举措有望支持公司未来的持续增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.